Malpractice claims for pancreatic cancer in Norway: claim-rates, injury domains, claim outcomes and indemnity compensation
DOI:
https://doi.org/10.2340/ao.v65.45500Keywords:
Pancreatic cancer, diagnosticsAbstract
ABSTRACT
Background and purpose: Pancreatic cancer is difficult to diagnose early and at a curative stage, yet little is known about errors in management. The aim of the study was to investigate malpractice claims in Norway.
Patients and Methods: All malpractice claims filed to the Norwegian System of Patient Injury Compensation between 2015 and 2024 for pancreatic cancer were evaluated.
Results: A total of 148 claims (median 15 [range 8–20] claims/year) were filed among 9548 patients with pancreatic cancer, for an average claim rate of 1.55% (1 claim per every 65 pancreatic cancers). Most claims were filed against hospital/specialists (n = 90), followed by general practitioners (n = 49) with nine claims towards private practice contractors (P < 0.001). A total of 33 claims (22.3%) were approved, of which 28 (85%) concerned delayed diagnosis. Radiology was involved in 18 of the 33 approvals. According to caretaker-level for the malpractice claim, approved claims were 23% for hospital-claims, with lowest approval-rate against general practitioners (12%), and highest against private contractors (66%). Median delay in diagnosis was estimated at 6 months. The outcome of the error was ‘death’ in 16 of 33. Prognostic loss was determined in five of 33 patients, while 12 patients had no prognostic loss despite an approved claim. Caretaker-level did not differ regarding death or prognostic loss in claims (P = 0.203). A total of 1.47 million EUR was paid in indemnity payments.
Interpretation: The claim rate of 1.5% was stable, with about one in five claims approved. Diagnostic delay was the predominant cause, with several stakeholders involved across the healthcare system.
Downloads
References
Mannucci A, Goel A. Advances in pancreatic cancer early diagnosis, prevention, and treatment: the past, the present, and the future. CA Cancer J Clin. 2026;76(1):e70035.
https://doi.org/10.3322/caac.70035 DOI: https://doi.org/10.3322/caac.70035
GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.
Shen MJ, Jamali A, Katona BW. Challenges of early detection of pancreatic cancer. J Clin Invest. 2025 Oct 15;135(20):e191942.
https://doi.org/10.1172/JCI191942 DOI: https://doi.org/10.1172/JCI191942
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987–1002.
https://doi.org/10.1016/j.annonc.2023.08.009 DOI: https://doi.org/10.1016/j.annonc.2023.08.009
Søreide K, Rangelova E, Dopazo C, Mieog S, Stättner S. Pancreatic cancer. Eur J Surg Oncol. 2023;49(2):521–5.
https://doi.org/10.1016/j.ejso.2023.01.001 DOI: https://doi.org/10.1016/j.ejso.2023.01.001
Olakotan O, Yargawa J, Moreland JA, Friedemann Smith C,
Nicholson BD, Millar A, et al. Characteristics of optimal cancer referrals made by primary care clinicians: scoping review. Cancer Control. 2025;32:10732748251359405. DOI: https://doi.org/10.1177/10732748251359405
Black GB, Nicholson BD, Moreland JA, Fulop NJ, Lyratzopoulos G, Baxter R. Doing ‘detective work’ to find a cancer: how are non-specific symptom pathways for cancer investigation organised, and what are the implications for safety and quality of care? A multisite qualitative approach. BMJ Qual Saf. 2025;34(7):457–68.
https://doi.org/10.1136/bmjqs-2024-017749 DOI: https://doi.org/10.1136/bmjqs-2024-017749
van Dongen JC, van der Geest LGM, de Meijer VE, van Santvoort HC, de Vos-Geelen J, Besselink MG, et al. Age and prognosis in patients with pancreatic cancer: a population-based study. Acta Oncol. 2022;61(3):286–93. DOI: https://doi.org/10.1080/0284186X.2021.2016949
Singh H, Sethi S, Raber M, Petersen LA. Errors in cancer diagnosis: current understanding and future directions. J Clin Oncol. 2007;25(31):5009–18.
https://doi.org/10.1200/JCO.2007.13.2142 DOI: https://doi.org/10.1200/JCO.2007.13.2142
Ravlo M, Lieng M, Khan Bukholm IR, Haase Moen M, Vanky E. Claims for compensation from women with cervical cancer in Norway – a retrospective, descriptive study of a 12-year period. Acta Obstet Gynecol Scand. 2020;99(11):1546–53.
https://doi.org/10.1111/aogs.13930 DOI: https://doi.org/10.1111/aogs.13930
Hafström L, Johansson H, Ahlberg J. Does diagnostic delay of colorectal cancer result in malpractice claims? A retrospective analysis of the Swedish board of malpractice from 1995–2008. Patient Saf Surg. 2012;6(1):13.
https://doi.org/10.1186/1754-9493-6-13 DOI: https://doi.org/10.1186/1754-9493-6-13
Doolin JW, Schaffer AC, Tishler RB, Jacobson JO. An analysis of medical malpractice claims against medical oncologists from a national database: implications for safer practice. J Healthc Risk Manag. 2024;43(3):18–28.
https://doi.org/10.1002/jhrm.21563 DOI: https://doi.org/10.1002/jhrm.21563
Chang S, Daskivich TJ, Vasquez M, Sacks WL, Zumsteg ZS,
Ho AS. Malpractice trends involving active surveillance across
cancers. Ann Surg. 2024;279(4):679–83.
https://doi.org/10.1097/SLA.0000000000006101 DOI: https://doi.org/10.1097/SLA.0000000000006101
Jørstad RG. The Norwegian system of compensation to patients. Med Law. 2002;21(4):681–6.
Rosenkrantz AB, Siegal D, Skillings JA, Muellner A, Nass SJ, Hricak H. Oncologic errors in diagnostic radiology: a 10-year analysis based on medical malpractice claims. J Am Coll Radiol. 2021;18(9):1310–6.
https://doi.org/10.1016/j.jacr.2021.05.001 DOI: https://doi.org/10.1016/j.jacr.2021.05.001
Mokienko A. Effects of a reimbursement change and travel times on the delivery of private and public radiology services in Norway: a register-based longitudinal study of Norwegian claims data. Cost Eff Resour Alloc. 2019;17:22.
https://doi.org/10.1186/s12962-019-0190-7 DOI: https://doi.org/10.1186/s12962-019-0190-7
Ansari D, Søreide K, Andersson B, Hansen CP, Seppänen H, Sparrelid E, et al. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Scand J Gastroenterol. 2024;59(9):1097–104.
https://doi.org/10.1080/00365521.2024.2378948 DOI: https://doi.org/10.1080/00365521.2024.2378948
Søreide K, Møller JH, Strand K, Søreide AH, Hodne S, Karlsen LN. Malpractice and compensation claims for acute pancreatitis in Norway: characteristics of claimants, claim-rates, outcomes and indemnity compensation. Scand J Gastroenterol. 2025;60(10):1032–42.
https://doi.org/10.1080/00365521.2025.2537280 DOI: https://doi.org/10.1080/00365521.2025.2537280
Skjold-Ødegaard B, Braut GS, Ersdal HL, Søreide K. Claims filed after perceived malpractice in management of acute appendicitis: an observational nationwide cohort study. Scand J Surg. 2025;114(4):414–20. DOI: https://doi.org/10.1177/14574969251363823
Aae TF, Jakobsen RB, Bukholm IRK, Fenstad AM, Furnes O, Randsborg PH. Compensation claims after hip arthroplasty surgery in Norway 2008–2018. Acta Orthop. 2021;92(3):311–5. DOI: https://doi.org/10.1080/17453674.2021.1872901
17453674.2021.1872901
Holman A, McKeown E, Quinn M, Parikh ND, Tapper EB. Medical malpractice claims in hepatology: rates, reasons, and results. Hepatol Commun. 2023;7(5).
https://doi.org/10.1097/HC9.0000000000000122 DOI: https://doi.org/10.1097/HC9.0000000000000122
Nilbert M. Changing before we have to; how to mitigate disparities in pancreatic cancer care? Acta Oncol. 2022;61(3):275–6.
https://doi.org/10.1080/0284186X.2022.2041720 DOI: https://doi.org/10.1080/0284186X.2022.2041720
Søreide K, Ismail W, Roalsø M, Ghotbi J, Zaharia C. Early diagnosis of pancreatic cancer: clinical premonitions, timely precursor detection and increased curative-intent surgery. Cancer Control. 2023;30:10732748231154711.
https://doi.org/10.1177/10732748231154711 DOI: https://doi.org/10.1177/10732748231154711
Kulkarni NM, Soloff EV, Tolat PP, Sangster GP, Fleming JB, Brook OR, et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology’s disease-focused panel for pancreatic ductal adenocarcinoma: part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol (NY). 2020;45(3):716–28.
https://doi.org/10.1007/s00261-019-02289-5 DOI: https://doi.org/10.1007/s00261-019-02289-5
Kohan, A., Grant, R.C., Henault, D. et al. AI-Based Segmentation Reduces the Retrospective Miss Rate of Pancreatic Ductal Adenocarcinoma. J Digit Imaging. Inform. med. (2025). https://doi.org/10.1007/s10278-025-01792-0 DOI: https://doi.org/10.1007/s10278-025-01792-0
Alves N, Schuurmans M, Rutkowski D, Saha A, Vendittelli P, Obuchowski N, et al. Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study. Lancet Oncol. 2026;27(1):116–24.
https://doi.org/10.1016/S1470-2045(25)00567-4 DOI: https://doi.org/10.1016/S1470-2045(25)00567-4
Published
How to Cite
License
Copyright (c) 2026 Annbjørg H Søreide, Karin H. Edland, Andreas B. Alvestad, Solveig Hodne, Kjetil Søreide
This work is licensed under a Creative Commons Attribution 4.0 International License.
